Ambrx Biopharma Inc. (AMAM) |
|
5.06 -0.28 (-5.24%)
|
01-21 17:37 |
|
Open: |
5.3 |
Pre. Close: |
5.34 |
|
High:
|
5.73 |
Low:
|
4.9028 |
|
Volume:
|
19,613 |
Market Cap:
|
177M |
|
|
|
|
Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the Ã? and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. Ambrx Biopharma Inc. has collaborations with various pharmaceutical companies, which include Bristol Myers Squibb Company; AbbVie Inc.; Astellas Pharma Inc.; and Elanco Animal Health. The company was founded in 2003 and is based in La Jolla, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.742 - 5.777 |
5.777 - 5.802 |
|
Low:
|
4.828 - 4.868 |
4.868 - 4.898 |
|
Close:
|
5.006 - 5.067 |
5.067 - 5.112 |
|
Technical analysis |
as of: 2022-01-21 4:24:42 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 9.71 One year: 12.17 |
| Support: |
Support1: 4.90 Support2: 4.08 |
| Resistance: |
Resistance1: 8.31 Resistance2: 10.42 |
| Pivot: |
7.14 |
| Moving Average: |
MA(5): 5.63 MA(20): 7.62
MA(100): 11.50 MA(250): |
| MACD: |
MACD(12,26): -1.12 Signal(9): -0.89 |
| Stochastic oscillator: |
%K(14,3): 5.54 %D(3): 11.36 |
| RSI: |
RSI(14): 19.02 |
| 52-week: |
High: 22.87 Low: 4.90 Change(%): -70.3 |
| Average Vol(K): |
3-Month: 18 10-Days: 23 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.AMAM has closed above bottom band by 12.4%. Bollinger Bands are 75.6% wider than normal. The large width of the bands suggest high volatility as compared to Ambrx Biopharma Inc.'s normal range. The bands have been in this wide range for 4 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Tue, 04 Jan 2022
Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director - Business Wire
Wed, 29 Dec 2021
Ambrx Biopharma (AMAM) Sees Hammer Chart Pattern: Time to Buy? - Entrepreneur
Thu, 09 Dec 2021
Ambrx Biopharma Stock (AMAM): Why The Price Jumped Today - Pulse 2.0
Mon, 06 Dec 2021
Ambrx Biopharma Inc - ADR Shares Fall 3.6% Below Previous 52-Week Low - Market Mover - Nasdaq
Fri, 19 Nov 2021
Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium - Yahoo Finance
Mon, 01 Nov 2021
Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference - Business Wire
|
Financial Analysis |
| Growth |
NA |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
NA |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
NA |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
NA |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Neutral |
Discounted cash flow: |
Neutral |
| Return on Assets: |
Neutral |
Price to Earnings: |
Neutral |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
35 |
| Shares Float (M) |
14 |
|
% Held by Insiders
|
|
|
% Held by Institutions
|
38.92 |
|
Shares Short (K)
|
3 |
|
Shares Short P. Month (K)
|
3 |
Stock Financials |
|
EPS
|
-4.970 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
5.520 |
|
Profit Margin
|
|
|
Operating Margin
|
-262.70 |
|
Return on Assets (ttm)
|
|
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
-20.8 |
|
Gross Profit (p.s.)
|
0.391 |
|
Sales Per Share
|
0.352 |
|
EBITDA (p.s.)
|
-0.870 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-40 |
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
-1.02 |
|
PEG Ratio
|
|
|
Price to Book value
|
0.92 |
|
Price to Sales
|
14.36 |
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
